Published in Health Business Week, October 20th, 2006
"This is an important advancement for our existing technology because it will allow us to reach an even broader population," said Dr. Rick Bright, Novavax's vice president of Vaccine Development. "There are many parts of the world that do not have accessibility to enough sterile needles to respond to an influenza crisis."
Historically influenza vaccines have been administered though intramuscular injection. However, the World Health Organization (WHO) has...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.